Microbiological Etiology and Susceptibility of Bacterial Conjunctivitis Isolates from Clinical Trials with Ophthalmic, Twice-Daily Besifloxacin
- 278 Downloads
Bacterial conjunctivitis is a contagious infection of the surface of the eye usually treated empirically with topical antibiotics. Since the etiologic agent is rarely identified, it is important to monitor which bacteria cause conjunctivitis and determine their antibacterial resistance profiles.
A total of 496 bacterial samples were isolated during a randomized, double-masked, vehicle-controlled, parallel-group study conducted in the United States with besifloxacin ophthalmic suspension 0.6% dosed twice daily. Species were determined by standard biochemical and/or molecular identification methods. Minimum inhibitory concentrations were determined according to Clinical and Laboratory Standards Institute standards.
The most prevalent species was Haemophilus influenzae, followed by Staphylococcus epidermidis, Staphylococcus aureus, the Streptococcus mitis group, and Streptococcus pneumoniae. One species identified in this study, which was not previously noted as a common cause of bacterial conjunctivitis, was Dolosigranulum pigrum. Ampicillin resistance was common among H. influenzae isolates, while macrolide resistance was high among S. pneumoniae, S. epidermidis, and S. aureus. The latter two species also included a number of isolates resistant to methicillin and ciprofloxacin.
Antibiotic resistance among isolates remains a concern and the appearance of an emerging ocular pathogen, D. pigrum, suggests the need for continued observation. The topical ophthalmic fluoroquinolones continue to provide a good balance of low to moderate (i.e., manageable) levels of resistance plus broad-spectrum coverage for empiric treatment of ocular infections.
KeywordsAntimicrobial efficacy Bacterial conjunctivitis Besifloxacin Fluoroquinolone Ophthalmic suspension
Unable to display preview. Download preview PDF.
- 5.American Academy of Ophthalmology. American Academy of Ophthalmology Cornea/External Disease Panel; Preferred Practice Pattern Guidelines. Conjunctivitis. San Francisco, CA: American Academy of Ophthalmology; 2008.Google Scholar
- 20.Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin Ther. 2011;33:13–26.PubMedCrossRefGoogle Scholar
- 23.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement M100-S21. 31. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2011.Google Scholar
- 25.Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. Washington, D.C.: ASM Press; 2007.Google Scholar
- 26.Leighton C, Piper D, Gunerman-King J. Pneumococcal conjunctivitis at an elementary school—Maine, September 20–December 6, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:64–66.Google Scholar
- 29.Sanfilippo CM, Haas W, Hesje CK, Morris TW. Strain ST448 causes the majority of pneumococcal conjunctivitis cases. Abstract A226. Paper presented at: Annual meeting of The Association for Research in Vision and Ophthalmology; May 6, 2012; Ft. Lauderdale, Florida, USA.Google Scholar